AC Immune to Present at Jefferies Global Healthcare Conference 2026
Globe Newswire•11/11/2026•07:00 ET
0
Key Highlights
- ➤AC Immune (ACIU) to present at Jefferies Global Healthcare Conference November 18
- ➤ACI-7104 Phase 2 candidate targets early-stage Parkinson’s disease
- ➤Martin Zügel to discuss ACI-19764 and small-molecule Morphomer program
- ➤AC Immune collaborations offer more than $4.5 billion in potential milestone payments
Expert Statements
Martin Zügel, Interim CEO of AC Immune
“During the session, Martin will discuss AC Immune’s lead candidate, ACI-7104, an anti-alpha-synuclein (a-syn) active immunotherapy in Phase 2 development for early-stage Parkinson’s disease, alongside updates on the Company’s wholly-owned portfolio, including ACI-19764 and its small-molecule Morphomer targeting a-syn.”
AC Immune to Present at Jefferies Global Healthcare Conference 2026
Lausanne, Switzerland, November 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, today announced that Martin Zügel, Interim CEO, will present and participate in a fireside chat at the annual Jefferies Global Healthcare Conference 2026, taking place November 16-19 in London, UK.
Get started
Create a free account to read the full story.